Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

References

• National Institutes of Health. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH consensus statement online. 1998; 16: 1–37. http://www.consensus.nih.gov. Accessed November 22, 2007.
   Google Scholar
• Burd L, Klug MG, Coumbe MJ, Kerbeshian J. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol. 2003; 18(8): 555–561.
   PubMedGoogle Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005; 366(9481): 237–248.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Hinshaw SP. Externalizing behavior problems and academic under-achievement in childhood and adolescence: causal relationships and underlying mechanisms. Psychol Bull. 1992; 111(1): 127–155.
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996,53(5): 437–146.
   PubMed Web of Science ®Google Scholar
• Liu YH, Stein MT. Attention-deficit/hyperactivity disorder: evidence-based diagnosis and management for primary care clinicians. Minerva Pediatr. 2004; 56(6): 567–583.
   PubMedGoogle Scholar
• Williams LM, Hermens DF, Palmer D, et al. Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biol Psychiatry. 2008; 63(10): 917–926.
   PubMed Web of Science ®Google Scholar
• Clarke SD, Kohn MR, Hermens DF, et al. Distinguishing symptom profiles in adolescent ADHD using an objective cognitive test battery. Int J Adolesc Med Health. 2007; 19(3): 355–367.
   PubMedGoogle Scholar
• Escobar R, Hervas A, Soutullo C, Mardomingo M, Uruñuela A, Gilaberte I. Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children, [published online ahead of print February 28, 2008], Actas Esp Psiquiatr.
   Google Scholar
• Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr. 2007; 7(1 Suppl): 121–131.
   PubMedGoogle Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999; 56(12): 1073–1086.
   PubMed Web of Science ®Google Scholar
• Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit-hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psych. 1997; 54(9): 857–864.
   PubMedGoogle Scholar
• Goldman LS, Genel M, Bezman RJ, Slanetz PS. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998; 279(14): 1100–1007.
   PubMed Web of Science ®Google Scholar
• Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med. 1999; 340(10): 780–788.
   PubMedGoogle Scholar
• Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006; 8(4): 4.
   PubMedGoogle Scholar
• Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape Psychiatry and Mental Health 2003; 8. http://www.medscape.com/viewarticle/461543. Accessed March 5, 2008.
   Google Scholar
• Harris Interactive® fielded an online survey. Data on file. Novartis Pharmaceuticals Corp; 2008.
   Google Scholar
• Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004; 10(4 Suppl): S117–S124.
   PubMedGoogle Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta® methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001; 107(6): E105.
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS® methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108(4): 883–892.
   PubMed Web of Science ®Google Scholar
• Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR®) in children attention deficit/hyperactivity disorder. Pediatrics. 2002; 110(2 pt 1): 258–266.
   PubMed Web of Science ®Google Scholar
• Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Pediatr Drugs. 2003; 5(12): 833–841.
   PubMedGoogle Scholar
• Lopez F, Silva R, Pestreich L, et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin® LATM and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr Drugs. 2003; 5(8): 545–555.
   PubMedGoogle Scholar
• McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SL1381 (Adderall XR®), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003; 42(6): 673–683.
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al; the COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS Study). Pediatrics. 2004; 113(3 pt 1): e206–e216.
   PubMed Web of Science ®Google Scholar
• Silva R, Pestreich LK, Brams M, Childress A, Lopez FA. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol. 2005; 15(4): 637–654.
   PubMed Web of Science ®Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention-deficit/hyperactivity disorder. J Atten Disords. 2005; 9(1): 275–289.
   PubMedGoogle Scholar
• Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006; 45(7): 817–823.
   PubMed Web of Science ®Google Scholar
• McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006; 9(3): 476–485.
   PubMedGoogle Scholar
• Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006; 16(3): 239–251.
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, McGough J, Findling R. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007; 29(3): 450–463.
   PubMed Web of Science ®Google Scholar
• Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo- controlled, crossover analog classroom study. Biol Psychiatry. 2007; 62(9): 970–976.
   PubMed Web of Science ®Google Scholar
• Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2008; 69: 149–159. Erratum in: J Clin Psychiatry. 2008;69(1): 329.
   PubMedGoogle Scholar
• Muniz R, Brams M, Mao A, McCague K, Silva R. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention deficit hyperactivity disorder: A 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008; 18(3): 248–256.
   PubMed Web of Science ®Google Scholar
• Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008; 47(2): 199–208.
   PubMed Web of Science ®Google Scholar
• Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull. 2008; 41(1): 19–33.
   PubMed Web of Science ®Google Scholar
• Dexedrine® (dextroamphetamine sulfate) spansule sustained-release capsules and tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
   Google Scholar
• James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 2001; 40(11): 1268–1276.
   PubMed Web of Science ®Google Scholar
• Adderall XR® (amphetamine) capsules prescribing information [package insert], Florence, KY: Shire US Inc. 2007.
   Google Scholar
• Concerta® (methylphenidate HCl) extended-release tablets CII [package insert]. Fort Washington, PA: McNeil-PPC, Inc. 2007.
   Google Scholar
• DaytranaTM(methylphenidate transdermal system) [package insert]. Wayne, PA: Shire US Inc. 2007.
   Google Scholar
• Focalin® XR (dexmethylphenidate hydrochloride) extended-release capsules [package insert]. Summit, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• Metadate CD® (methylphenidate HCl) extended-release capsules [package insert], Rochester, NY: UCB, Inc. 2007.
   Google Scholar
• Ritalin LA® (methylphenidate hydrochloride) extended-release capsules [package insert]. Summit, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• VyvanseTM (lisdexamfetamine dismesylate) [package insert], Blacksburg, VA: New River Pharmaceuticals Inc. 2007.
   Google Scholar
• Strattera® (atomoxetine HCI). Indianapolis, IN: Eli Lilly and Company; 2007.
   Google Scholar
• Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull. 1998; 34(1): 55–60.
   PubMedGoogle Scholar
• Wigal S, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998; 34(1): 47–53.
   PubMedGoogle Scholar
• Conners CK. Ratings scales in attention deficit/hyperactivity disorder: in assessment and treatment monitoring. J Clin Psychiatry. 1998; 59(suppl 7): 24–30.
   PubMed Web of Science ®Google Scholar
• Pelham WE, Milich R, Murphy DA, Murphy HA. Normative data on the IOWA Conners teacher rating scale. J Clin Child Psychol. 1989; 18: 259–262.
   Google Scholar
• DuPaul A, Power T, Anastapolous A, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
   Google Scholar
• Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001; 5: 39–47.
   Google Scholar
• Swanson JM, Agier D, Fineberg E, et al. University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In: Greenhill LL, Osman BB, eds. Ritalin: Theory and Practice. New York: Mary Ann Liebert; 2000: 405–132.
   Google Scholar
• Swanson J, Lerner M, Wigal T, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord. 2002; 6(suppl 1): S73–S88.
   PubMedGoogle Scholar
• Brown RT, Amler RW, Freeman WS, et al; American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005; 115(6): e749–e757.
   PubMedGoogle Scholar
• Ding YS, Fowler JS, Volkow ND, Logan J, Gatley SJ, Sugano Y. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med. 1995; 36(12): 2298–2305.
   PubMedGoogle Scholar
• Ding YS, Fowler JS, Volkow ND, Logan J, Gatley SJ, Sugano Y. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Beri). 1997; 131(1): 71–80.
   PubMed Web of Science ®Google Scholar
• Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006; 20(9): 713–738.
   PubMedGoogle Scholar
• Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002; 6(suppl 1): S31–S43.
   PubMedGoogle Scholar
• Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004; 43(11): 1422–1429.
   PubMed Web of Science ®Google Scholar
• Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004; 43(11): 1406–1414.
   PubMed Web of Science ®Google Scholar
• Arnold LE, Lindsay RL, Conners CK, et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2004; 14(4): 542–554.
   PubMedGoogle Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003; 60(2): 204–211.
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lis-dexamfetamine dimesylate in health adult volunteers. Curr Med Res Opin. 2008; 24(1): 33–40.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004; 65(10): 1301–1313.
   PubMed Web of Science ®Google Scholar
• Dickstein SG, Bannon K, Castellanos FX, Milham MP. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry. 2006; 47(10): 1051–1062.
   PubMed Web of Science ®Google Scholar
• Mattay VS, Berman KF, Ostrem JL, et al. Dextroamphetamine enhances “neural network-specific” physiological signals: a positron-emission tomography rCBF study. J Neurosci. 1996; 16(15): 4816–4822.
   PubMedGoogle Scholar
• Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(11): 1410–1415.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998; 155(10): 1325–1331.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001; 21(2): RC 121.
   Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003; 23(10): 1281–1299.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Pliszka S, Dulcan M, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002; 41(suppl 2): S26–S49.
   PubMed Web of Science ®Google Scholar